Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
McKinsey
Johnson and Johnson
Express Scripts

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MILNACIPRAN HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Milnacipran Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00098124 Study of Milnacipran for the Treatment of Fibromyalgia Completed Forest Laboratories Phase 3 2004-11-01 Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.
NCT00225511 Study Evaluating Effexor XR for Major Depression. Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2004-06-01 Study Evaluating Effexor XR for Major Depression.
NCT00314249 Study of Milnacipran for the Treatment of Fibromyalgia Completed Cypress Bioscience, Inc. Phase 3 2006-04-01 The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
NCT00314249 Study of Milnacipran for the Treatment of Fibromyalgia Completed Forest Laboratories Phase 3 2006-04-01 The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
NCT00436033 A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome Completed Pierre Fabre Medicament Phase 3 2006-02-01 Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.
NCT00606203 Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke? Unknown status Chang Gung Memorial Hospital N/A 2007-09-01 Depression is one of the important psychiatric sequelae after stroke. The prevalence of post stroke depression (PSD) is approximately 20-40%. Depression comorbid with stroke has been found to be associated with increased disability, cognitive function decline, poorer rehabilitation outcome and higher mortality rate.We are going to conduct a trial of prevention of psot stroke depression by prescribing milnacipran in advance.
NCT00618956 A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring Completed Cypress Bioscience, Inc. Phase 3 2007-10-01 The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Milnacipran Hydrochloride

Condition Name

Condition Name for Milnacipran Hydrochloride
Intervention Trials
Fibromyalgia 19
Depression 7
Fibromyalgia Syndrome 3
Chronic Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Milnacipran Hydrochloride
Intervention Trials
Fibromyalgia 27
Myofascial Pain Syndromes 26
Depression 6
Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Milnacipran Hydrochloride

Trials by Country

Trials by Country for Milnacipran Hydrochloride
Location Trials
United States 206
Japan 19
Korea, Republic of 5
France 4
Romania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Milnacipran Hydrochloride
Location Trials
California 12
New York 11
North Carolina 11
Florida 10
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Milnacipran Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Milnacipran Hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Milnacipran Hydrochloride
Clinical Trial Phase Trials
Completed 29
Unknown status 8
Recruiting 7
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Milnacipran Hydrochloride

Sponsor Name

Sponsor Name for Milnacipran Hydrochloride
Sponsor Trials
Forest Laboratories 29
Cypress Bioscience, Inc. 6
Samsung Medical Center 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Milnacipran Hydrochloride
Sponsor Trials
Other 49
Industry 43
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Mallinckrodt
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.